#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Results and Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-10	Results	abstract	new	_	_
1-3	11-14	and	_	_	_	_
1-4	15-25	Discussion	abstract	new	_	_

#Text=During the drug design process , to assess the potential druggability of a compound as a new starting point , some initial rules like drug-likeness ( as defined by Lipinski and colleagues in 1997 ) , lead-likeness ( as defined by Oprea ) and known drug space , are usually applied .
2-1	26-32	During	_	_	_	_
2-2	33-36	the	abstract[5]	new[5]	_	_
2-3	37-41	drug	substance|abstract[5]	new|new[5]	coref	2-46
2-4	42-48	design	abstract|abstract[5]	new|new[5]	_	_
2-5	49-56	process	abstract[5]	new[5]	_	_
2-6	57-58	,	_	_	_	_
2-7	59-61	to	_	_	_	_
2-8	62-68	assess	_	_	_	_
2-9	69-72	the	substance[6]	new[6]	_	_
2-10	73-82	potential	substance[6]	new[6]	_	_
2-11	83-95	druggability	substance[6]	new[6]	_	_
2-12	96-98	of	substance[6]	new[6]	_	_
2-13	99-100	a	substance[6]|substance[7]	new[6]|new[7]	coref	3-8[0_7]
2-14	101-109	compound	substance[6]|substance[7]	new[6]|new[7]	_	_
2-15	110-112	as	substance[6]	new[6]	_	_
2-16	113-114	a	substance[6]|abstract[8]	new[6]|new[8]	_	_
2-17	115-118	new	substance[6]|abstract[8]	new[6]|new[8]	_	_
2-18	119-127	starting	substance[6]|abstract[8]	new[6]|new[8]	_	_
2-19	128-133	point	substance[6]|abstract[8]	new[6]|new[8]	_	_
2-20	134-135	,	_	_	_	_
2-21	136-140	some	abstract[9]	new[9]	coref	3-4[18_9]
2-22	141-148	initial	abstract[9]	new[9]	_	_
2-23	149-154	rules	abstract[9]	new[9]	_	_
2-24	155-159	like	abstract[9]	new[9]	_	_
2-25	160-173	drug-likeness	abstract[9]|substance[10]	new[9]|new[10]	_	_
2-26	174-175	(	abstract[9]|substance[10]	new[9]|new[10]	_	_
2-27	176-178	as	abstract[9]|substance[10]	new[9]|new[10]	_	_
2-28	179-186	defined	abstract[9]|substance[10]	new[9]|new[10]	_	_
2-29	187-189	by	abstract[9]|substance[10]	new[9]|new[10]	_	_
2-30	190-198	Lipinski	abstract[9]|substance[10]|person	new[9]|new[10]|new	_	_
2-31	199-202	and	abstract[9]|substance[10]	new[9]|new[10]	_	_
2-32	203-213	colleagues	abstract[9]|substance[10]|person	new[9]|new[10]|new	_	_
2-33	214-216	in	abstract[9]|substance[10]	new[9]|new[10]	_	_
2-34	217-221	1997	abstract[9]|substance[10]|time	new[9]|new[10]|new	_	_
2-35	222-223	)	abstract[9]|substance[10]	new[9]|new[10]	_	_
2-36	224-225	,	abstract[9]	new[9]	_	_
2-37	226-239	lead-likeness	abstract[9]|substance[14]	new[9]|new[14]	_	_
2-38	240-241	(	abstract[9]|substance[14]	new[9]|new[14]	_	_
2-39	242-244	as	abstract[9]|substance[14]	new[9]|new[14]	_	_
2-40	245-252	defined	abstract[9]|substance[14]	new[9]|new[14]	_	_
2-41	253-255	by	abstract[9]|substance[14]	new[9]|new[14]	_	_
2-42	256-261	Oprea	abstract[9]|substance[14]|abstract	new[9]|new[14]|new	_	_
2-43	262-263	)	abstract[9]|substance[14]	new[9]|new[14]	_	_
2-44	264-267	and	abstract[9]	new[9]	_	_
2-45	268-273	known	abstract[9]|abstract[17]	new[9]|new[17]	ana	4-5[0_17]
2-46	274-278	drug	abstract[9]|substance|abstract[17]	new[9]|giv|new[17]	_	_
2-47	279-284	space	abstract[9]|abstract[17]	new[9]|new[17]	_	_
2-48	285-286	,	_	_	_	_
2-49	287-290	are	_	_	_	_
2-50	291-298	usually	_	_	_	_
2-51	299-306	applied	_	_	_	_
2-52	307-308	.	_	_	_	_

#Text=In general , the rules to characterise/filter compound collections are based upon physicochemical parameters , e.g. , logP , logS , MW , TPSA , MR , RotN , HBA and HBD , among others .
3-1	309-311	In	_	_	_	_
3-2	312-319	general	_	_	_	_
3-3	320-321	,	_	_	_	_
3-4	322-325	the	abstract[18]	giv[18]	coref	6-15[50_18]
3-5	326-331	rules	abstract[18]	giv[18]	_	_
3-6	332-334	to	abstract[18]	giv[18]	_	_
3-7	335-354	characterise/filter	abstract[18]	giv[18]	_	_
3-8	355-363	compound	abstract[18]|substance|abstract[20]	giv[18]|giv|new[20]	coref	22-7
3-9	364-375	collections	abstract[18]|abstract[20]	giv[18]|new[20]	_	_
3-10	376-379	are	_	_	_	_
3-11	380-385	based	_	_	_	_
3-12	386-390	upon	_	_	_	_
3-13	391-406	physicochemical	abstract[21]	new[21]	appos	3-16[22_21]
3-14	407-417	parameters	abstract[21]	new[21]	_	_
3-15	418-419	,	_	_	_	_
3-16	420-424	e.g.	abstract[22]|abstract[23]	giv[22]|giv[23]	appos|appos	3-16[23_22]|3-20[0_23]
3-17	425-426	,	abstract[22]|abstract[23]	giv[22]|giv[23]	_	_
3-18	427-431	logP	abstract[22]|abstract[23]	giv[22]|giv[23]	_	_
3-19	432-433	,	abstract[23]	giv[23]	_	_
3-20	434-438	logS	abstract[23]|abstract	giv[23]|giv	appos	3-22
3-21	439-440	,	abstract[23]	giv[23]	_	_
3-22	441-443	MW	abstract[23]|abstract	giv[23]|giv	appos	3-24
3-23	444-445	,	abstract[23]	giv[23]	_	_
3-24	446-450	TPSA	abstract[23]|abstract	giv[23]|giv	appos	3-26
3-25	451-452	,	abstract[23]	giv[23]	_	_
3-26	453-455	MR	abstract[23]|abstract	giv[23]|giv	appos	3-28
3-27	456-457	,	abstract[23]	giv[23]	_	_
3-28	458-462	RotN	abstract[23]|abstract	giv[23]|giv	appos	3-30
3-29	463-464	,	abstract[23]	giv[23]	_	_
3-30	465-468	HBA	abstract[23]|abstract	giv[23]|giv	appos	3-32[30_0]
3-31	469-472	and	abstract[23]	giv[23]	_	_
3-32	473-476	HBD	abstract[23]|abstract[30]	giv[23]|giv[30]	_	_
3-33	477-478	,	abstract[23]|abstract[30]	giv[23]|giv[30]	_	_
3-34	479-484	among	abstract[23]|abstract[30]	giv[23]|giv[30]	_	_
3-35	485-491	others	abstract[23]|abstract[30]	giv[23]|giv[30]	_	_
3-36	492-493	.	_	_	_	_

#Text=As a result , it would be interesting to assess how proteasome inhibitors are positioned with respect to the typically expected “ drug-like ” chemical space .
4-1	494-496	As	_	_	_	_
4-2	497-498	a	abstract[31]	new[31]	_	_
4-3	499-505	result	abstract[31]	new[31]	_	_
4-4	506-507	,	_	_	_	_
4-5	508-510	it	abstract	giv	coref	4-19[34_0]
4-6	511-516	would	_	_	_	_
4-7	517-519	be	_	_	_	_
4-8	520-531	interesting	_	_	_	_
4-9	532-534	to	_	_	_	_
4-10	535-541	assess	_	_	_	_
4-11	542-545	how	_	_	_	_
4-12	546-556	proteasome	abstract[33]	new[33]	coref	5-12[38_33]
4-13	557-567	inhibitors	abstract[33]	new[33]	_	_
4-14	568-571	are	_	_	_	_
4-15	572-582	positioned	_	_	_	_
4-16	583-587	with	_	_	_	_
4-17	588-595	respect	_	_	_	_
4-18	596-598	to	_	_	_	_
4-19	599-602	the	abstract[34]	giv[34]	coref	6-6[0_34]
4-20	603-612	typically	abstract[34]	giv[34]	_	_
4-21	613-621	expected	abstract[34]	giv[34]	_	_
4-22	622-623	“	abstract[34]	giv[34]	_	_
4-23	624-633	drug-like	abstract[34]	giv[34]	_	_
4-24	634-635	”	abstract[34]	giv[34]	_	_
4-25	636-644	chemical	abstract[34]	giv[34]	_	_
4-26	645-650	space	abstract[34]	giv[34]	_	_
4-27	651-652	.	_	_	_	_

#Text=To do so , we performed a comprehensive analysis of the 680 small-molecules proteasome inhibitors dataset spanning a large range of activity ( 0.08 nM < IC50 ≤ 150,000 nM ) .
5-1	653-655	To	_	_	_	_
5-2	656-658	do	_	_	_	_
5-3	659-661	so	_	_	_	_
5-4	662-663	,	_	_	_	_
5-5	664-666	we	person	acc	ana	11-3
5-6	667-676	performed	_	_	_	_
5-7	677-678	a	abstract[36]	new[36]	_	_
5-8	679-692	comprehensive	abstract[36]	new[36]	_	_
5-9	693-701	analysis	abstract[36]	new[36]	_	_
5-10	702-704	of	abstract[36]	new[36]	_	_
5-11	705-708	the	abstract[36]|abstract[39]	new[36]|new[39]	coref	8-1[64_39]
5-12	709-712	680	abstract[36]|abstract[38]|abstract[39]	new[36]|giv[38]|new[39]	coref	10-11[84_38]
5-13	713-728	small-molecules	abstract[36]|abstract[38]|abstract[39]	new[36]|giv[38]|new[39]	_	_
5-14	729-739	proteasome	abstract[36]|abstract|abstract[38]|abstract[39]	new[36]|new|giv[38]|new[39]	coref	7-17
5-15	740-750	inhibitors	abstract[36]|abstract[38]|abstract[39]	new[36]|giv[38]|new[39]	_	_
5-16	751-758	dataset	abstract[36]|abstract[39]	new[36]|new[39]	_	_
5-17	759-767	spanning	abstract[36]|abstract[39]	new[36]|new[39]	_	_
5-18	768-769	a	abstract[36]|abstract[39]|abstract[40]	new[36]|new[39]|new[40]	_	_
5-19	770-775	large	abstract[36]|abstract[39]|abstract[40]	new[36]|new[39]|new[40]	_	_
5-20	776-781	range	abstract[36]|abstract[39]|abstract[40]	new[36]|new[39]|new[40]	_	_
5-21	782-784	of	abstract[36]|abstract[39]|abstract[40]	new[36]|new[39]|new[40]	_	_
5-22	785-793	activity	abstract[36]|abstract[39]|abstract[40]|abstract	new[36]|new[39]|new[40]|new	coref	7-17[63_0]
5-23	794-795	(	_	_	_	_
5-24	796-800	0.08	_	_	_	_
5-25	801-803	nM	_	_	_	_
5-26	804-805	<	_	_	_	_
5-27	806-810	IC50	abstract[42]	new[42]	_	_
5-28	811-812	≤	abstract[42]	new[42]	_	_
5-29	813-820	150,000	abstract[42]|abstract[43]	new[42]|new[43]	ana	6-1[0_43]
5-30	821-823	nM	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-31	824-825	)	_	_	_	_
5-32	826-827	.	_	_	_	_

#Text=This entailed looking at chemical space distribution , scaffold similarity and the extraction of chemical rules with machine learning , using either direct structural information ( scaffolds and Morgan fingerprints ) or being based on 21 general molecular ( QuaSAR ) descriptors .
6-1	828-832	This	abstract	giv	_	_
6-2	833-841	entailed	_	_	_	_
6-3	842-849	looking	_	_	_	_
6-4	850-852	at	_	_	_	_
6-5	853-861	chemical	abstract[46]	new[46]	coref	10-3[80_46]
6-6	862-867	space	abstract|abstract[46]	giv|new[46]	coref	10-4
6-7	868-880	distribution	abstract[46]	new[46]	_	_
6-8	881-882	,	_	_	_	_
6-9	883-891	scaffold	abstract|abstract[48]	new|new[48]	coref|coref	10-8|10-7[82_48]
6-10	892-902	similarity	abstract[48]	new[48]	_	_
6-11	903-906	and	_	_	_	_
6-12	907-910	the	event[49]	new[49]	_	_
6-13	911-921	extraction	event[49]	new[49]	_	_
6-14	922-924	of	event[49]	new[49]	_	_
6-15	925-933	chemical	event[49]|abstract[50]	new[49]|giv[50]	_	_
6-16	934-939	rules	event[49]|abstract[50]	new[49]|giv[50]	_	_
6-17	940-944	with	event[49]	new[49]	_	_
6-18	945-952	machine	event[49]|object|abstract[52]	new[49]|new|new[52]	_	_
6-19	953-961	learning	event[49]|abstract[52]	new[49]|new[52]	_	_
6-20	962-963	,	_	_	_	_
6-21	964-969	using	_	_	_	_
6-22	970-976	either	abstract[53]	new[53]	coref	12-23[95_53]
6-23	977-983	direct	abstract[53]	new[53]	_	_
6-24	984-994	structural	abstract[53]	new[53]	_	_
6-25	995-1006	information	abstract[53]	new[53]	_	_
6-26	1007-1008	(	_	_	_	_
6-27	1009-1018	scaffolds	object	new	coref	24-10[173_0]
6-28	1019-1022	and	_	_	_	_
6-29	1023-1029	Morgan	person|object[56]	new|new[56]	_	_
6-30	1030-1042	fingerprints	object[56]	new[56]	_	_
6-31	1043-1044	)	_	_	_	_
6-32	1045-1047	or	_	_	_	_
6-33	1048-1053	being	_	_	_	_
6-34	1054-1059	based	_	_	_	_
6-35	1060-1062	on	_	_	_	_
6-36	1063-1065	21	abstract[58]	new[58]	coref	12-16[94_58]
6-37	1066-1073	general	abstract[58]	new[58]	_	_
6-38	1074-1083	molecular	abstract[58]	new[58]	_	_
6-39	1084-1085	(	abstract[58]	new[58]	_	_
6-40	1086-1092	QuaSAR	abstract|abstract[58]	new|new[58]	_	_
6-41	1093-1094	)	abstract[58]	new[58]	_	_
6-42	1095-1106	descriptors	abstract[58]	new[58]	_	_
6-43	1107-1108	.	_	_	_	_

#Text=This set of analyses was ultimately employed to produce meaningful chemical patterns that are correlated with proteasome inhibitory activity .
7-1	1109-1113	This	abstract[59]	new[59]	_	_
7-2	1114-1117	set	abstract[59]	new[59]	_	_
7-3	1118-1120	of	abstract[59]	new[59]	_	_
7-4	1121-1129	analyses	abstract[59]|abstract	new[59]|new	_	_
7-5	1130-1133	was	_	_	_	_
7-6	1134-1144	ultimately	_	_	_	_
7-7	1145-1153	employed	_	_	_	_
7-8	1154-1156	to	_	_	_	_
7-9	1157-1164	produce	_	_	_	_
7-10	1165-1175	meaningful	abstract[61]	new[61]	_	_
7-11	1176-1184	chemical	abstract[61]	new[61]	_	_
7-12	1185-1193	patterns	abstract[61]	new[61]	_	_
7-13	1194-1198	that	abstract[61]	new[61]	_	_
7-14	1199-1202	are	abstract[61]	new[61]	_	_
7-15	1203-1213	correlated	abstract[61]	new[61]	_	_
7-16	1214-1218	with	abstract[61]	new[61]	_	_
7-17	1219-1229	proteasome	abstract[61]|abstract|abstract[63]	new[61]|giv|giv[63]	coref|coref	8-6|8-6[66_63]
7-18	1230-1240	inhibitory	abstract[61]|abstract[63]	new[61]|giv[63]	_	_
7-19	1241-1249	activity	abstract[61]|abstract[63]	new[61]|giv[63]	_	_
7-20	1250-1251	.	_	_	_	_

#Text=The dataset comprises only human proteasome activity data for the CT-L catalytic site , as this is the only site with the largest number of compounds , and is divided into four classes .
8-1	1252-1255	The	abstract[64]	giv[64]	coref	24-22[177_64]
8-2	1256-1263	dataset	abstract[64]	giv[64]	_	_
8-3	1264-1273	comprises	_	_	_	_
8-4	1274-1278	only	abstract[67]	new[67]	coref	9-1[75_67]
8-5	1279-1284	human	abstract[67]	new[67]	_	_
8-6	1285-1295	proteasome	abstract|abstract[66]|abstract[67]	giv|giv[66]|new[67]	coref|coref	10-11|16-11[0_66]
8-7	1296-1304	activity	abstract[66]|abstract[67]	giv[66]|new[67]	_	_
8-8	1305-1309	data	abstract[67]	new[67]	_	_
8-9	1310-1313	for	abstract[67]	new[67]	_	_
8-10	1314-1317	the	abstract[67]|place[69]	new[67]|new[69]	ana	8-16[0_69]
8-11	1318-1322	CT-L	abstract[67]|substance|place[69]	new[67]|new|new[69]	_	_
8-12	1323-1332	catalytic	abstract[67]|place[69]	new[67]|new[69]	_	_
8-13	1333-1337	site	abstract[67]|place[69]	new[67]|new[69]	_	_
8-14	1338-1339	,	_	_	_	_
8-15	1340-1342	as	_	_	_	_
8-16	1343-1347	this	place	giv	coref	8-18[71_0]
8-17	1348-1350	is	_	_	_	_
8-18	1351-1354	the	place[71]	giv[71]	_	_
8-19	1355-1359	only	place[71]	giv[71]	_	_
8-20	1360-1364	site	place[71]	giv[71]	_	_
8-21	1365-1369	with	place[71]	giv[71]	_	_
8-22	1370-1373	the	place[71]|abstract[72]	giv[71]|new[72]	_	_
8-23	1374-1381	largest	place[71]|abstract[72]	giv[71]|new[72]	_	_
8-24	1382-1388	number	place[71]|abstract[72]	giv[71]|new[72]	_	_
8-25	1389-1391	of	place[71]|abstract[72]	giv[71]|new[72]	_	_
8-26	1392-1401	compounds	place[71]|abstract[72]|substance	giv[71]|new[72]|new	coref	16-18[113_0]
8-27	1402-1403	,	_	_	_	_
8-28	1404-1407	and	_	_	_	_
8-29	1408-1410	is	_	_	_	_
8-30	1411-1418	divided	_	_	_	_
8-31	1419-1423	into	_	_	_	_
8-32	1424-1428	four	abstract[74]	new[74]	coref	16-9[112_74]
8-33	1429-1436	classes	abstract[74]	new[74]	_	_
8-34	1437-1438	.	_	_	_	_

#Text=Full data are available in Table S1 .
9-1	1439-1443	Full	abstract[75]	giv[75]	_	_
9-2	1444-1448	data	abstract[75]	giv[75]	_	_
9-3	1449-1452	are	_	_	_	_
9-4	1453-1462	available	_	_	_	_
9-5	1463-1465	in	_	_	_	_
9-6	1466-1471	Table	abstract	new	_	_
9-7	1472-1474	S1	abstract	new	coref	12-28
9-8	1475-1476	.	_	_	_	_

#Text=Analysis of chemical space distribution and the scaffold similarity of proteasome inhibitors .
10-1	1477-1485	Analysis	abstract[78]	new[78]	coref	12-3[90_78]
10-2	1486-1488	of	abstract[78]	new[78]	_	_
10-3	1489-1497	chemical	abstract[78]|abstract[80]	new[78]|giv[80]	coref	11-5[89_80]
10-4	1498-1503	space	abstract[78]|abstract|abstract[80]	new[78]|giv|giv[80]	coref	11-9[88_0]
10-5	1504-1516	distribution	abstract[78]|abstract[80]	new[78]|giv[80]	_	_
10-6	1517-1520	and	abstract[78]	new[78]	_	_
10-7	1521-1524	the	abstract[78]|abstract[82]	new[78]|giv[82]	coref	22-11[157_82]
10-8	1525-1533	scaffold	abstract[78]|abstract|abstract[82]	new[78]|giv|giv[82]	_	_
10-9	1534-1544	similarity	abstract[78]|abstract[82]	new[78]|giv[82]	_	_
10-10	1545-1547	of	abstract[78]|abstract[82]	new[78]|giv[82]	_	_
10-11	1548-1558	proteasome	abstract[78]|abstract[82]|abstract|abstract[84]	new[78]|giv[82]|giv|giv[84]	coref|coref	11-6|11-5[87_84]
10-12	1559-1569	inhibitors	abstract[78]|abstract[82]|abstract[84]	new[78]|giv[82]|giv[84]	_	_
10-13	1570-1571	.	_	_	_	_

#Text=First , we analyzed human proteasome inhibitors ’ chemical space distribution .
11-1	1572-1577	First	_	_	_	_
11-2	1578-1579	,	_	_	_	_
11-3	1580-1582	we	person	giv	ana	21-34
11-4	1583-1591	analyzed	_	_	_	_
11-5	1592-1597	human	abstract[87]|abstract[89]	giv[87]|giv[89]	coref	20-33[144_87]
11-6	1598-1608	proteasome	abstract|abstract[87]|abstract[89]	giv|giv[87]|giv[89]	coref	20-34
11-7	1609-1619	inhibitors	abstract[87]|abstract[89]	giv[87]|giv[89]	_	_
11-8	1620-1621	’	abstract[87]|abstract[89]	giv[87]|giv[89]	_	_
11-9	1622-1630	chemical	abstract[88]|abstract[89]	giv[88]|giv[89]	coref	12-6[91_88]
11-10	1631-1636	space	abstract[88]|abstract[89]	giv[88]|giv[89]	_	_
11-11	1637-1649	distribution	abstract[89]	giv[89]	_	_
11-12	1650-1651	.	_	_	_	_

#Text=To address this analysis , chemical space was defined by the t-SNE calculation applied to the 21 calculated molecular descriptors listed in the Supplementary Information ( Table S1 ) .
12-1	1652-1654	To	_	_	_	_
12-2	1655-1662	address	_	_	_	_
12-3	1663-1667	this	abstract[90]	giv[90]	_	_
12-4	1668-1676	analysis	abstract[90]	giv[90]	_	_
12-5	1677-1678	,	_	_	_	_
12-6	1679-1687	chemical	abstract[91]	giv[91]	coref	13-34[107_91]
12-7	1688-1693	space	abstract[91]	giv[91]	_	_
12-8	1694-1697	was	_	_	_	_
12-9	1698-1705	defined	_	_	_	_
12-10	1706-1708	by	_	_	_	_
12-11	1709-1712	the	abstract[93]	new[93]	_	_
12-12	1713-1718	t-SNE	abstract|abstract[93]	new|new[93]	_	_
12-13	1719-1730	calculation	abstract[93]	new[93]	_	_
12-14	1731-1738	applied	abstract[93]	new[93]	_	_
12-15	1739-1741	to	abstract[93]	new[93]	_	_
12-16	1742-1745	the	abstract[93]|abstract[94]	new[93]|giv[94]	coref	21-31[151_94]
12-17	1746-1748	21	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
12-18	1749-1759	calculated	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
12-19	1760-1769	molecular	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
12-20	1770-1781	descriptors	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
12-21	1782-1788	listed	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
12-22	1789-1791	in	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
12-23	1792-1795	the	abstract[93]|abstract[94]|abstract[95]	new[93]|giv[94]|giv[95]	_	_
12-24	1796-1809	Supplementary	abstract[93]|abstract[94]|abstract[95]	new[93]|giv[94]|giv[95]	_	_
12-25	1810-1821	Information	abstract[93]|abstract[94]|abstract[95]	new[93]|giv[94]|giv[95]	_	_
12-26	1822-1823	(	_	_	_	_
12-27	1824-1829	Table	_	_	_	_
12-28	1830-1832	S1	abstract	giv	_	_
12-29	1833-1834	)	_	_	_	_
12-30	1835-1836	.	_	_	_	_

#Text=The proximity in a t-SNE plot is relative in nature , and the distance between points simply represents relative proximity ( i.e. , it is not a direct scaling from real distances in the 21 dimensional space ) .
13-1	1837-1840	The	abstract[97]	new[97]	coref	13-19[103_97]
13-2	1841-1850	proximity	abstract[97]	new[97]	_	_
13-3	1851-1853	in	abstract[97]	new[97]	_	_
13-4	1854-1855	a	abstract[97]|abstract[99]	new[97]|new[99]	coref	16-44[121_99]
13-5	1856-1861	t-SNE	abstract[97]|person|abstract[99]	new[97]|new|new[99]	_	_
13-6	1862-1866	plot	abstract[97]|abstract[99]	new[97]|new[99]	_	_
13-7	1867-1869	is	_	_	_	_
13-8	1870-1878	relative	_	_	_	_
13-9	1879-1881	in	_	_	_	_
13-10	1882-1888	nature	abstract	new	_	_
13-11	1889-1890	,	_	_	_	_
13-12	1891-1894	and	_	_	_	_
13-13	1895-1898	the	abstract[101]	new[101]	_	_
13-14	1899-1907	distance	abstract[101]	new[101]	_	_
13-15	1908-1915	between	abstract[101]	new[101]	_	_
13-16	1916-1922	points	abstract[101]|place	new[101]|new	_	_
13-17	1923-1929	simply	_	_	_	_
13-18	1930-1940	represents	_	_	_	_
13-19	1941-1949	relative	abstract[103]	giv[103]	ana	13-24[0_103]
13-20	1950-1959	proximity	abstract[103]	giv[103]	_	_
13-21	1960-1961	(	_	_	_	_
13-22	1962-1966	i.e.	_	_	_	_
13-23	1967-1968	,	_	_	_	_
13-24	1969-1971	it	abstract	giv	_	_
13-25	1972-1974	is	_	_	_	_
13-26	1975-1978	not	_	_	_	_
13-27	1979-1980	a	abstract[105]	new[105]	_	_
13-28	1981-1987	direct	abstract[105]	new[105]	_	_
13-29	1988-1995	scaling	abstract[105]	new[105]	_	_
13-30	1996-2000	from	abstract[105]	new[105]	_	_
13-31	2001-2005	real	abstract[105]|abstract[106]	new[105]|new[106]	_	_
13-32	2006-2015	distances	abstract[105]|abstract[106]	new[105]|new[106]	_	_
13-33	2016-2018	in	abstract[105]|abstract[106]	new[105]|new[106]	_	_
13-34	2019-2022	the	abstract[105]|abstract[106]|abstract[107]	new[105]|new[106]|giv[107]	coref	21-21[149_107]
13-35	2023-2025	21	abstract[105]|abstract[106]|abstract[107]	new[105]|new[106]|giv[107]	_	_
13-36	2026-2037	dimensional	abstract[105]|abstract[106]|abstract[107]	new[105]|new[106]|giv[107]	_	_
13-37	2038-2043	space	abstract[105]|abstract[106]|abstract[107]	new[105]|new[106]|giv[107]	_	_
13-38	2044-2045	)	_	_	_	_
13-39	2046-2047	.	_	_	_	_

#Text=In
14-1	2048-2050	In	_	_	_	_

#Text=Figure 4
15-1	2051-2057	Figure	abstract[108]	new[108]	coref	17-1[129_108]
15-2	2058-2059	4	abstract[108]	new[108]	_	_

#Text=( left ) the difference of distribution of the four activity classes is easily perceptible , with the most active compounds ( class A , purple ) having close to half of its compounds ( ~47 % ) in the top-right quadrant of the plot , while the least active compounds ( class D , orange ) are mainly concentrated in the bottom-left quadrant ( ~58 % of class D compounds ) , as quantified in
16-1	2060-2061	(	_	_	_	_
16-2	2062-2066	left	_	_	_	_
16-3	2067-2068	)	_	_	_	_
16-4	2069-2072	the	abstract[109]	new[109]	_	_
16-5	2073-2083	difference	abstract[109]	new[109]	_	_
16-6	2084-2086	of	abstract[109]	new[109]	_	_
16-7	2087-2099	distribution	abstract[109]|abstract[110]	new[109]|new[110]	coref	19-12[133_110]
16-8	2100-2102	of	abstract[109]|abstract[110]	new[109]|new[110]	_	_
16-9	2103-2106	the	abstract[109]|abstract[110]|abstract[112]	new[109]|new[110]|giv[112]	coref	20-14[139_112]
16-10	2107-2111	four	abstract[109]|abstract[110]|abstract[112]	new[109]|new[110]|giv[112]	_	_
16-11	2112-2120	activity	abstract[109]|abstract[110]|abstract|abstract[112]	new[109]|new[110]|giv|giv[112]	coref	27-8
16-12	2121-2128	classes	abstract[109]|abstract[110]|abstract[112]	new[109]|new[110]|giv[112]	_	_
16-13	2129-2131	is	_	_	_	_
16-14	2132-2138	easily	_	_	_	_
16-15	2139-2150	perceptible	_	_	_	_
16-16	2151-2152	,	_	_	_	_
16-17	2153-2157	with	_	_	_	_
16-18	2158-2161	the	substance[113]	giv[113]	coref	16-33[118_113]
16-19	2162-2166	most	substance[113]	giv[113]	_	_
16-20	2167-2173	active	substance[113]	giv[113]	_	_
16-21	2174-2183	compounds	substance[113]	giv[113]	_	_
16-22	2184-2185	(	_	_	_	_
16-23	2186-2191	class	abstract[114]	new[114]	appos	16-26[0_114]
16-24	2192-2193	A	abstract[114]	new[114]	_	_
16-25	2194-2195	,	_	_	_	_
16-26	2196-2202	purple	abstract	giv	ana	16-33
16-27	2203-2204	)	_	_	_	_
16-28	2205-2211	having	_	_	_	_
16-29	2212-2217	close	time[116]	new[116]	_	_
16-30	2218-2220	to	time[116]	new[116]	_	_
16-31	2221-2225	half	time[116]	new[116]	_	_
16-32	2226-2228	of	time[116]	new[116]	_	_
16-33	2229-2232	its	time[116]|abstract|substance[118]	new[116]|giv|giv[118]	coref|appos	16-48[122_118]|16-53[123_0]
16-34	2233-2242	compounds	time[116]|substance[118]	new[116]|giv[118]	_	_
16-35	2243-2244	(	_	_	_	_
16-36	2245-2248	~47	abstract[119]	new[119]	_	_
16-37	2249-2250	%	abstract[119]	new[119]	_	_
16-38	2251-2252	)	_	_	_	_
16-39	2253-2255	in	_	_	_	_
16-40	2256-2259	the	abstract[120]	new[120]	coref	16-62[126_120]
16-41	2260-2269	top-right	abstract[120]	new[120]	_	_
16-42	2270-2278	quadrant	abstract[120]	new[120]	_	_
16-43	2279-2281	of	abstract[120]	new[120]	_	_
16-44	2282-2285	the	abstract[120]|abstract[121]	new[120]|giv[121]	_	_
16-45	2286-2290	plot	abstract[120]|abstract[121]	new[120]|giv[121]	_	_
16-46	2291-2292	,	_	_	_	_
16-47	2293-2298	while	_	_	_	_
16-48	2299-2302	the	substance[122]	giv[122]	coref	16-69[128_122]
16-49	2303-2308	least	substance[122]	giv[122]	_	_
16-50	2309-2315	active	substance[122]	giv[122]	_	_
16-51	2316-2325	compounds	substance[122]	giv[122]	_	_
16-52	2326-2327	(	_	_	_	_
16-53	2328-2333	class	abstract[123]	giv[123]	coref	20-4[138_123]
16-54	2334-2335	D	abstract[123]|person	giv[123]|new	_	_
16-55	2336-2337	,	abstract[123]	giv[123]	_	_
16-56	2338-2344	orange	abstract[123]|object	giv[123]|new	_	_
16-57	2345-2346	)	_	_	_	_
16-58	2347-2350	are	_	_	_	_
16-59	2351-2357	mainly	_	_	_	_
16-60	2358-2370	concentrated	_	_	_	_
16-61	2371-2373	in	_	_	_	_
16-62	2374-2377	the	abstract[126]	giv[126]	_	_
16-63	2378-2389	bottom-left	abstract[126]	giv[126]	_	_
16-64	2390-2398	quadrant	abstract[126]	giv[126]	_	_
16-65	2399-2400	(	_	_	_	_
16-66	2401-2404	~58	_	_	_	_
16-67	2405-2406	%	_	_	_	_
16-68	2407-2409	of	_	_	_	_
16-69	2410-2415	class	person[127]|substance[128]	new[127]|giv[128]	coref	24-42[0_128]
16-70	2416-2417	D	person[127]|substance[128]	new[127]|giv[128]	_	_
16-71	2418-2427	compounds	substance[128]	giv[128]	_	_
16-72	2428-2429	)	_	_	_	_
16-73	2430-2431	,	_	_	_	_
16-74	2432-2434	as	_	_	_	_
16-75	2435-2445	quantified	_	_	_	_
16-76	2446-2448	in	_	_	_	_

#Text=Figure 4
17-1	2449-2455	Figure	abstract[129]	giv[129]	_	_
17-2	2456-2457	4	abstract[129]	giv[129]	_	_

#Text=( right ) .
18-1	2458-2459	(	_	_	_	_
18-2	2460-2465	right	_	_	_	_
18-3	2466-2467	)	_	_	_	_
18-4	2468-2469	.	_	_	_	_

#Text=Classes B ( blue ) and C ( green ) have a more disperse distribution , but show some higher density areas close to the bottom-left corner .
19-1	2470-2477	Classes	person[130]	new[130]	_	_
19-2	2478-2479	B	person[130]	new[130]	_	_
19-3	2480-2481	(	_	_	_	_
19-4	2482-2486	blue	_	_	_	_
19-5	2487-2488	)	_	_	_	_
19-6	2489-2492	and	_	_	_	_
19-7	2493-2494	C	person[131]	new[131]	_	_
19-8	2495-2496	(	person[131]	new[131]	_	_
19-9	2497-2502	green	person[131]|abstract	new[131]|new	_	_
19-10	2503-2504	)	person[131]	new[131]	_	_
19-11	2505-2509	have	_	_	_	_
19-12	2510-2511	a	abstract[133]	giv[133]	ana	20-1[0_133]
19-13	2512-2516	more	abstract[133]	giv[133]	_	_
19-14	2517-2525	disperse	abstract[133]	giv[133]	_	_
19-15	2526-2538	distribution	abstract[133]	giv[133]	_	_
19-16	2539-2540	,	_	_	_	_
19-17	2541-2544	but	_	_	_	_
19-18	2545-2549	show	_	_	_	_
19-19	2550-2554	some	place[135]	new[135]	_	_
19-20	2555-2561	higher	abstract[134]|place[135]	new[134]|new[135]	_	_
19-21	2562-2569	density	abstract[134]|place[135]	new[134]|new[135]	_	_
19-22	2570-2575	areas	place[135]	new[135]	_	_
19-23	2576-2581	close	place[135]	new[135]	_	_
19-24	2582-2584	to	_	_	_	_
19-25	2585-2588	the	place[136]	new[136]	_	_
19-26	2589-2600	bottom-left	place[136]	new[136]	_	_
19-27	2601-2607	corner	place[136]	new[136]	_	_
19-28	2608-2609	.	_	_	_	_

#Text=This indicates that class D , for example , is fundamentally different to the remaining classes from a structural and physicochemical level , and therefore supports the existence of a SAR in the proteasome inhibitors developed in the last 20 years .
20-1	2610-2614	This	abstract	giv	coref	23-17[169_0]
20-2	2615-2624	indicates	_	_	_	_
20-3	2625-2629	that	_	_	_	_
20-4	2630-2635	class	abstract[138]	giv[138]	coref	21-9[147_138]
20-5	2636-2637	D	abstract[138]	giv[138]	_	_
20-6	2638-2639	,	_	_	_	_
20-7	2640-2643	for	_	_	_	_
20-8	2644-2651	example	_	_	_	_
20-9	2652-2653	,	_	_	_	_
20-10	2654-2656	is	_	_	_	_
20-11	2657-2670	fundamentally	_	_	_	_
20-12	2671-2680	different	_	_	_	_
20-13	2681-2683	to	_	_	_	_
20-14	2684-2687	the	abstract[139]	giv[139]	coref	23-15[0_139]
20-15	2688-2697	remaining	abstract[139]	giv[139]	_	_
20-16	2698-2705	classes	abstract[139]	giv[139]	_	_
20-17	2706-2710	from	_	_	_	_
20-18	2711-2712	a	abstract[140]	new[140]	_	_
20-19	2713-2723	structural	abstract[140]	new[140]	_	_
20-20	2724-2727	and	abstract[140]	new[140]	_	_
20-21	2728-2743	physicochemical	abstract[140]	new[140]	_	_
20-22	2744-2749	level	abstract[140]	new[140]	_	_
20-23	2750-2751	,	_	_	_	_
20-24	2752-2755	and	_	_	_	_
20-25	2756-2765	therefore	_	_	_	_
20-26	2766-2774	supports	_	_	_	_
20-27	2775-2778	the	abstract[141]	new[141]	_	_
20-28	2779-2788	existence	abstract[141]	new[141]	_	_
20-29	2789-2791	of	abstract[141]	new[141]	_	_
20-30	2792-2793	a	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-31	2794-2797	SAR	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-32	2798-2800	in	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-33	2801-2804	the	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|giv[144]	coref	22-14[158_144]
20-34	2805-2815	proteasome	abstract[141]|abstract[142]|abstract|abstract[144]	new[141]|new[142]|giv|giv[144]	_	_
20-35	2816-2826	inhibitors	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|giv[144]	_	_
20-36	2827-2836	developed	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|giv[144]	_	_
20-37	2837-2839	in	abstract[141]|abstract[142]|abstract[144]	new[141]|new[142]|giv[144]	_	_
20-38	2840-2843	the	abstract[141]|abstract[142]|abstract[144]|time[145]	new[141]|new[142]|giv[144]|new[145]	_	_
20-39	2844-2848	last	abstract[141]|abstract[142]|abstract[144]|time[145]	new[141]|new[142]|giv[144]|new[145]	_	_
20-40	2849-2851	20	abstract[141]|abstract[142]|abstract[144]|time[145]	new[141]|new[142]|giv[144]|new[145]	_	_
20-41	2852-2857	years	abstract[141]|abstract[142]|abstract[144]|time[145]	new[141]|new[142]|giv[144]|new[145]	_	_
20-42	2858-2859	.	_	_	_	_

#Text=Additionally , no particular cluster was formed with a single class , which means there is no particular location in chemical space ( at least one that is defined by the descriptors that we considered ) which is reserved to one single class .
21-1	2860-2872	Additionally	_	_	_	_
21-2	2873-2874	,	_	_	_	_
21-3	2875-2877	no	abstract[146]	new[146]	_	_
21-4	2878-2888	particular	abstract[146]	new[146]	_	_
21-5	2889-2896	cluster	abstract[146]	new[146]	_	_
21-6	2897-2900	was	_	_	_	_
21-7	2901-2907	formed	_	_	_	_
21-8	2908-2912	with	_	_	_	_
21-9	2913-2914	a	abstract[147]	giv[147]	coref	21-41[153_147]
21-10	2915-2921	single	abstract[147]	giv[147]	_	_
21-11	2922-2927	class	abstract[147]	giv[147]	_	_
21-12	2928-2929	,	abstract[147]	giv[147]	_	_
21-13	2930-2935	which	abstract[147]	giv[147]	_	_
21-14	2936-2941	means	abstract[147]	giv[147]	_	_
21-15	2942-2947	there	abstract[147]	giv[147]	_	_
21-16	2948-2950	is	abstract[147]	giv[147]	_	_
21-17	2951-2953	no	place[148]	new[148]	_	_
21-18	2954-2964	particular	place[148]	new[148]	_	_
21-19	2965-2973	location	place[148]	new[148]	_	_
21-20	2974-2976	in	place[148]	new[148]	_	_
21-21	2977-2985	chemical	place[148]|abstract[149]	new[148]|giv[149]	coref	23-18[168_149]
21-22	2986-2991	space	place[148]|abstract[149]	new[148]|giv[149]	_	_
21-23	2992-2993	(	_	_	_	_
21-24	2994-2996	at	abstract[150]	new[150]	_	_
21-25	2997-3002	least	abstract[150]	new[150]	_	_
21-26	3003-3006	one	abstract[150]	new[150]	_	_
21-27	3007-3011	that	abstract[150]	new[150]	_	_
21-28	3012-3014	is	abstract[150]	new[150]	_	_
21-29	3015-3022	defined	abstract[150]	new[150]	_	_
21-30	3023-3025	by	abstract[150]	new[150]	_	_
21-31	3026-3029	the	abstract[150]|abstract[151]	new[150]|giv[151]	_	_
21-32	3030-3041	descriptors	abstract[150]|abstract[151]	new[150]|giv[151]	_	_
21-33	3042-3046	that	abstract[150]|abstract[151]	new[150]|giv[151]	_	_
21-34	3047-3049	we	abstract[150]|abstract[151]|person	new[150]|giv[151]|giv	ana	23-3
21-35	3050-3060	considered	abstract[150]|abstract[151]	new[150]|giv[151]	_	_
21-36	3061-3062	)	_	_	_	_
21-37	3063-3068	which	_	_	_	_
21-38	3069-3071	is	_	_	_	_
21-39	3072-3080	reserved	_	_	_	_
21-40	3081-3083	to	_	_	_	_
21-41	3084-3087	one	abstract[153]	giv[153]	coref	24-13[174_153]
21-42	3088-3094	single	abstract[153]	giv[153]	_	_
21-43	3095-3100	class	abstract[153]	giv[153]	_	_
21-44	3101-3102	.	_	_	_	_

#Text=This observation indicates that carrying out compound selection biased for physicochemical similarity to known inhibitors might be a good initial filter to enrich the set of compound candidates with active hits .
22-1	3103-3107	This	abstract[154]	new[154]	coref	30-4[211_154]
22-2	3108-3119	observation	abstract[154]	new[154]	_	_
22-3	3120-3129	indicates	_	_	_	_
22-4	3130-3134	that	_	_	_	_
22-5	3135-3143	carrying	_	_	_	_
22-6	3144-3147	out	_	_	_	_
22-7	3148-3156	compound	substance|abstract[156]	giv|new[156]	coref	22-27
22-8	3157-3166	selection	abstract[156]	new[156]	_	_
22-9	3167-3173	biased	abstract[156]	new[156]	_	_
22-10	3174-3177	for	abstract[156]	new[156]	_	_
22-11	3178-3193	physicochemical	abstract[156]|abstract[157]	new[156]|giv[157]	coref	24-7[171_157]
22-12	3194-3204	similarity	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
22-13	3205-3207	to	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
22-14	3208-3213	known	abstract[156]|abstract[157]|abstract[158]	new[156]|giv[157]|giv[158]	_	_
22-15	3214-3224	inhibitors	abstract[156]|abstract[157]|abstract[158]	new[156]|giv[157]|giv[158]	_	_
22-16	3225-3230	might	_	_	_	_
22-17	3231-3233	be	_	_	_	_
22-18	3234-3235	a	abstract[159]	new[159]	_	_
22-19	3236-3240	good	abstract[159]	new[159]	_	_
22-20	3241-3248	initial	abstract[159]	new[159]	_	_
22-21	3249-3255	filter	abstract[159]	new[159]	_	_
22-22	3256-3258	to	abstract[159]	new[159]	_	_
22-23	3259-3265	enrich	abstract[159]	new[159]	_	_
22-24	3266-3269	the	abstract[159]|abstract[160]	new[159]|new[160]	_	_
22-25	3270-3273	set	abstract[159]|abstract[160]	new[159]|new[160]	_	_
22-26	3274-3276	of	abstract[159]|abstract[160]	new[159]|new[160]	_	_
22-27	3277-3285	compound	abstract[159]|abstract[160]|substance|animal[162]	new[159]|new[160]|giv|new[162]	_	_
22-28	3286-3296	candidates	abstract[159]|abstract[160]|animal[162]	new[159]|new[160]|new[162]	_	_
22-29	3297-3301	with	abstract[159]|abstract[160]|animal[162]	new[159]|new[160]|new[162]	_	_
22-30	3302-3308	active	abstract[159]|abstract[160]|animal[162]|abstract[163]	new[159]|new[160]|new[162]|new[163]	_	_
22-31	3309-3313	hits	abstract[159]|abstract[160]|animal[162]|abstract[163]	new[159]|new[160]|new[162]|new[163]	_	_
22-32	3314-3315	.	_	_	_	_

#Text=Next , we wanted to investigate what characteristics are responsible for the differences between classes in the chemical space distribution .
23-1	3316-3320	Next	_	_	_	_
23-2	3321-3322	,	_	_	_	_
23-3	3323-3325	we	person	giv	ana	24-16
23-4	3326-3332	wanted	_	_	_	_
23-5	3333-3335	to	_	_	_	_
23-6	3336-3347	investigate	_	_	_	_
23-7	3348-3352	what	abstract[165]	new[165]	_	_
23-8	3353-3368	characteristics	abstract[165]	new[165]	_	_
23-9	3369-3372	are	_	_	_	_
23-10	3373-3384	responsible	_	_	_	_
23-11	3385-3388	for	_	_	_	_
23-12	3389-3392	the	abstract[166]	new[166]	_	_
23-13	3393-3404	differences	abstract[166]	new[166]	_	_
23-14	3405-3412	between	abstract[166]	new[166]	_	_
23-15	3413-3420	classes	abstract[166]|abstract	new[166]|giv	coref	24-34[179_0]
23-16	3421-3423	in	abstract[166]	new[166]	_	_
23-17	3424-3427	the	abstract[166]|abstract[169]	new[166]|giv[169]	coref	28-17[194_169]
23-18	3428-3436	chemical	abstract[166]|abstract[168]|abstract[169]	new[166]|giv[168]|giv[169]	coref	30-6[0_168]
23-19	3437-3442	space	abstract[166]|abstract[168]|abstract[169]	new[166]|giv[168]|giv[169]	_	_
23-20	3443-3455	distribution	abstract[166]|abstract[169]	new[166]|giv[169]	_	_
23-21	3456-3457	.	_	_	_	_

#Text=Upon applying the Tc to characterize the similarity between Murcko scaffolds within each class , we observed a high diversity in the dataset , not just within each class , but also between the different classes , with most pairs of compounds showing a Tc below 0.5 that represents a considerable dissimilarity (
24-1	3458-3462	Upon	_	_	_	_
24-2	3463-3471	applying	_	_	_	_
24-3	3472-3475	the	abstract[170]	new[170]	coref	24-44[182_170]
24-4	3476-3478	Tc	abstract[170]	new[170]	_	_
24-5	3479-3481	to	_	_	_	_
24-6	3482-3494	characterize	_	_	_	_
24-7	3495-3498	the	abstract[171]	giv[171]	coref	27-10[0_171]
24-8	3499-3509	similarity	abstract[171]	giv[171]	_	_
24-9	3510-3517	between	abstract[171]	giv[171]	_	_
24-10	3518-3524	Murcko	abstract[171]|person|object[173]	giv[171]|new|giv[173]	coref	28-1[190_173]
24-11	3525-3534	scaffolds	abstract[171]|object[173]	giv[171]|giv[173]	_	_
24-12	3535-3541	within	abstract[171]	giv[171]	_	_
24-13	3542-3546	each	abstract[171]|abstract[174]	giv[171]|giv[174]	coref	24-26[178_174]
24-14	3547-3552	class	abstract[171]|abstract[174]	giv[171]|giv[174]	_	_
24-15	3553-3554	,	_	_	_	_
24-16	3555-3557	we	person	giv	_	_
24-17	3558-3566	observed	_	_	_	_
24-18	3567-3568	a	abstract[176]	new[176]	_	_
24-19	3569-3573	high	abstract[176]	new[176]	_	_
24-20	3574-3583	diversity	abstract[176]	new[176]	_	_
24-21	3584-3586	in	abstract[176]	new[176]	_	_
24-22	3587-3590	the	abstract[176]|abstract[177]	new[176]|giv[177]	_	_
24-23	3591-3598	dataset	abstract[176]|abstract[177]	new[176]|giv[177]	_	_
24-24	3599-3600	,	abstract[176]	new[176]	_	_
24-25	3601-3604	not	abstract[176]	new[176]	_	_
24-26	3605-3609	just	abstract[176]|abstract[178]	new[176]|giv[178]	coref	28-4[191_178]
24-27	3610-3616	within	abstract[176]|abstract[178]	new[176]|giv[178]	_	_
24-28	3617-3621	each	abstract[176]|abstract[178]	new[176]|giv[178]	_	_
24-29	3622-3627	class	abstract[176]|abstract[178]	new[176]|giv[178]	_	_
24-30	3628-3629	,	_	_	_	_
24-31	3630-3633	but	_	_	_	_
24-32	3634-3638	also	_	_	_	_
24-33	3639-3646	between	_	_	_	_
24-34	3647-3650	the	abstract[179]	giv[179]	coref	28-27[197_179]
24-35	3651-3660	different	abstract[179]	giv[179]	_	_
24-36	3661-3668	classes	abstract[179]	giv[179]	_	_
24-37	3669-3670	,	_	_	_	_
24-38	3671-3675	with	_	_	_	_
24-39	3676-3680	most	plant[180]	new[180]	_	_
24-40	3681-3686	pairs	plant[180]	new[180]	_	_
24-41	3687-3689	of	plant[180]	new[180]	_	_
24-42	3690-3699	compounds	plant[180]|substance	new[180]|giv	coref	28-35[199_0]
24-43	3700-3707	showing	_	_	_	_
24-44	3708-3709	a	abstract[182]	giv[182]	_	_
24-45	3710-3712	Tc	abstract[182]	giv[182]	_	_
24-46	3713-3718	below	abstract[182]	giv[182]	_	_
24-47	3719-3722	0.5	abstract[182]|abstract	giv[182]|new	_	_
24-48	3723-3727	that	abstract[182]	giv[182]	_	_
24-49	3728-3738	represents	abstract[182]	giv[182]	_	_
24-50	3739-3740	a	abstract[182]|abstract[184]	giv[182]|new[184]	_	_
24-51	3741-3753	considerable	abstract[182]|abstract[184]	giv[182]|new[184]	_	_
24-52	3754-3767	dissimilarity	abstract[182]|abstract[184]	giv[182]|new[184]	_	_
24-53	3768-3769	(	_	_	_	_

#Text=Figure 5
25-1	3770-3776	Figure	abstract[185]	new[185]	_	_
25-2	3777-3778	5	abstract[185]	new[185]	_	_

#Text=) .
26-1	3779-3780	)	_	_	_	_
26-2	3781-3782	.	_	_	_	_

#Text=Nonetheless a clear trend of correlation between activity and similarity is observed .
27-1	3783-3794	Nonetheless	_	_	_	_
27-2	3795-3796	a	abstract[186]	new[186]	_	_
27-3	3797-3802	clear	abstract[186]	new[186]	_	_
27-4	3803-3808	trend	abstract[186]	new[186]	_	_
27-5	3809-3811	of	abstract[186]	new[186]	_	_
27-6	3812-3823	correlation	abstract[186]|abstract[187]	new[186]|new[187]	_	_
27-7	3824-3831	between	abstract[186]|abstract[187]	new[186]|new[187]	_	_
27-8	3832-3840	activity	abstract[186]|abstract[187]|abstract	new[186]|new[187]|giv	coref	28-35[198_0]
27-9	3841-3844	and	abstract[186]|abstract[187]	new[186]|new[187]	_	_
27-10	3845-3855	similarity	abstract[186]|abstract[187]|abstract	new[186]|new[187]|giv	_	_
27-11	3856-3858	is	_	_	_	_
27-12	3859-3867	observed	_	_	_	_
27-13	3868-3869	.	_	_	_	_

#Text=The scaffolds of class B differ negligibly from class A , however , class C shows a two-peak distribution which suggests it contains scaffolds similar to both classes A/B , as well as with lower activity compounds ( class D ) .
28-1	3870-3873	The	object[190]	giv[190]	coref	28-24[196_190]
28-2	3874-3883	scaffolds	object[190]	giv[190]	_	_
28-3	3884-3886	of	object[190]	giv[190]	_	_
28-4	3887-3892	class	object[190]|abstract[191]	giv[190]|giv[191]	coref	28-9[192_191]
28-5	3893-3894	B	object[190]|abstract[191]	giv[190]|giv[191]	_	_
28-6	3895-3901	differ	_	_	_	_
28-7	3902-3912	negligibly	_	_	_	_
28-8	3913-3917	from	_	_	_	_
28-9	3918-3923	class	abstract[192]	giv[192]	coref	28-14[193_192]
28-10	3924-3925	A	abstract[192]	giv[192]	_	_
28-11	3926-3927	,	_	_	_	_
28-12	3928-3935	however	_	_	_	_
28-13	3936-3937	,	_	_	_	_
28-14	3938-3943	class	abstract[193]	giv[193]	coref	28-39[200_193]
28-15	3944-3945	C	abstract[193]	giv[193]	_	_
28-16	3946-3951	shows	_	_	_	_
28-17	3952-3953	a	abstract[194]	giv[194]	ana	28-22[0_194]
28-18	3954-3962	two-peak	abstract[194]	giv[194]	_	_
28-19	3963-3975	distribution	abstract[194]	giv[194]	_	_
28-20	3976-3981	which	abstract[194]	giv[194]	_	_
28-21	3982-3990	suggests	abstract[194]	giv[194]	_	_
28-22	3991-3993	it	abstract[194]|abstract	giv[194]|giv	_	_
28-23	3994-4002	contains	abstract[194]	giv[194]	_	_
28-24	4003-4012	scaffolds	abstract[194]|object[196]	giv[194]|giv[196]	coref	30-14[0_196]
28-25	4013-4020	similar	abstract[194]|object[196]	giv[194]|giv[196]	_	_
28-26	4021-4023	to	_	_	_	_
28-27	4024-4028	both	abstract[197]	giv[197]	_	_
28-28	4029-4036	classes	abstract[197]	giv[197]	_	_
28-29	4037-4040	A/B	abstract[197]	giv[197]	_	_
28-30	4041-4042	,	_	_	_	_
28-31	4043-4045	as	_	_	_	_
28-32	4046-4050	well	_	_	_	_
28-33	4051-4053	as	_	_	_	_
28-34	4054-4058	with	_	_	_	_
28-35	4059-4064	lower	abstract[198]|substance[199]	giv[198]|giv[199]	coref|coref	30-16[214_199]|31-12[219_198]
28-36	4065-4073	activity	abstract[198]|substance[199]	giv[198]|giv[199]	_	_
28-37	4074-4083	compounds	substance[199]	giv[199]	_	_
28-38	4084-4085	(	_	_	_	_
28-39	4086-4091	class	abstract[200]	giv[200]	ana	29-1[0_200]
28-40	4092-4093	D	abstract[200]	giv[200]	_	_
28-41	4094-4095	)	_	_	_	_
28-42	4096-4097	.	_	_	_	_

#Text=This is probably a result of the practical strategies applied in medicinal chemistry where inactive structures are modified/derivatized to meet or better resemble substructures seen among actives , thus creating this transition from A to D.
29-1	4098-4102	This	abstract	giv	coref	30-20[215_0]
29-2	4103-4105	is	_	_	_	_
29-3	4106-4114	probably	_	_	_	_
29-4	4115-4116	a	_	_	_	_
29-5	4117-4123	result	_	_	_	_
29-6	4124-4126	of	_	_	_	_
29-7	4127-4130	the	abstract[202]	new[202]	_	_
29-8	4131-4140	practical	abstract[202]	new[202]	_	_
29-9	4141-4151	strategies	abstract[202]	new[202]	_	_
29-10	4152-4159	applied	abstract[202]	new[202]	_	_
29-11	4160-4162	in	abstract[202]	new[202]	_	_
29-12	4163-4172	medicinal	abstract[202]|abstract[203]	new[202]|new[203]	_	_
29-13	4173-4182	chemistry	abstract[202]|abstract[203]	new[202]|new[203]	_	_
29-14	4183-4188	where	abstract[202]	new[202]	_	_
29-15	4189-4197	inactive	abstract[202]|abstract[204]	new[202]|new[204]	_	_
29-16	4198-4208	structures	abstract[202]|abstract[204]	new[202]|new[204]	_	_
29-17	4209-4212	are	abstract[202]	new[202]	_	_
29-18	4213-4233	modified/derivatized	abstract[202]	new[202]	_	_
29-19	4234-4236	to	abstract[202]	new[202]	_	_
29-20	4237-4241	meet	abstract[202]	new[202]	_	_
29-21	4242-4244	or	abstract[202]	new[202]	_	_
29-22	4245-4251	better	abstract[202]	new[202]	_	_
29-23	4252-4260	resemble	abstract[202]	new[202]	_	_
29-24	4261-4274	substructures	abstract[202]|abstract[205]	new[202]|new[205]	_	_
29-25	4275-4279	seen	abstract[202]|abstract[205]	new[202]|new[205]	_	_
29-26	4280-4285	among	abstract[202]|abstract[205]	new[202]|new[205]	_	_
29-27	4286-4293	actives	abstract[202]|abstract[205]|substance	new[202]|new[205]|new	coref	30-31[217_0]
29-28	4294-4295	,	_	_	_	_
29-29	4296-4300	thus	_	_	_	_
29-30	4301-4309	creating	_	_	_	_
29-31	4310-4314	this	event[207]	new[207]	ana	30-9[0_207]
29-32	4315-4325	transition	event[207]	new[207]	_	_
29-33	4326-4330	from	event[207]	new[207]	_	_
29-34	4331-4332	A	event[207]|abstract[208]	new[207]|new[208]	coref	31-33[0_208]
29-35	4333-4335	to	event[207]|abstract[208]	new[207]|new[208]	_	_
29-36	4336-4338	D.	event[207]|abstract[208]|person	new[207]|new[208]|new	_	_

#Text=As concluded from the chemical space observation , this also shows that functionalizing scaffolds from more potent compounds ( class A/B ) might be a feasible initial strategy to find new actives .
30-1	4339-4341	As	_	_	_	_
30-2	4342-4351	concluded	_	_	_	_
30-3	4352-4356	from	_	_	_	_
30-4	4357-4360	the	abstract[211]	giv[211]	_	_
30-5	4361-4369	chemical	abstract[211]	giv[211]	_	_
30-6	4370-4375	space	abstract|abstract[211]	giv|giv[211]	_	_
30-7	4376-4387	observation	abstract[211]	giv[211]	_	_
30-8	4388-4389	,	_	_	_	_
30-9	4390-4394	this	event	giv	_	_
30-10	4395-4399	also	_	_	_	_
30-11	4400-4405	shows	_	_	_	_
30-12	4406-4410	that	_	_	_	_
30-13	4411-4426	functionalizing	_	_	_	_
30-14	4427-4436	scaffolds	object	giv	coref	31-3[218_0]
30-15	4437-4441	from	_	_	_	_
30-16	4442-4446	more	substance[214]	giv[214]	_	_
30-17	4447-4453	potent	substance[214]	giv[214]	_	_
30-18	4454-4463	compounds	substance[214]	giv[214]	_	_
30-19	4464-4465	(	_	_	_	_
30-20	4466-4471	class	abstract[215]	giv[215]	coref	31-22[222_215]
30-21	4472-4475	A/B	abstract[215]	giv[215]	_	_
30-22	4476-4477	)	_	_	_	_
30-23	4478-4483	might	_	_	_	_
30-24	4484-4486	be	_	_	_	_
30-25	4487-4488	a	abstract[216]	new[216]	_	_
30-26	4489-4497	feasible	abstract[216]	new[216]	_	_
30-27	4498-4505	initial	abstract[216]	new[216]	_	_
30-28	4506-4514	strategy	abstract[216]	new[216]	_	_
30-29	4515-4517	to	abstract[216]	new[216]	_	_
30-30	4518-4522	find	abstract[216]	new[216]	_	_
30-31	4523-4526	new	abstract[216]|substance[217]	new[216]|giv[217]	_	_
30-32	4527-4534	actives	abstract[216]|substance[217]	new[216]|giv[217]	_	_
30-33	4535-4536	.	_	_	_	_

#Text=However , selected scaffolds should also be sufficiently dissimilar to the lower activity scaffolds , effectively avoiding the right-end tail of the class D ( i.e. , the most similar scaffolds to A , which are still largely inactive ) .
31-1	4537-4544	However	_	_	_	_
31-2	4545-4546	,	_	_	_	_
31-3	4547-4555	selected	object[218]	giv[218]	coref	31-11[220_218]
31-4	4556-4565	scaffolds	object[218]	giv[218]	_	_
31-5	4566-4572	should	_	_	_	_
31-6	4573-4577	also	_	_	_	_
31-7	4578-4580	be	_	_	_	_
31-8	4581-4593	sufficiently	_	_	_	_
31-9	4594-4604	dissimilar	_	_	_	_
31-10	4605-4607	to	_	_	_	_
31-11	4608-4611	the	object[220]	giv[220]	_	_
31-12	4612-4617	lower	abstract[219]|object[220]	giv[219]|giv[220]	_	_
31-13	4618-4626	activity	abstract[219]|object[220]	giv[219]|giv[220]	_	_
31-14	4627-4636	scaffolds	object[220]	giv[220]	_	_
31-15	4637-4638	,	_	_	_	_
31-16	4639-4650	effectively	_	_	_	_
31-17	4651-4659	avoiding	_	_	_	_
31-18	4660-4663	the	object[221]	new[221]	appos	31-26[223_221]
31-19	4664-4673	right-end	object[221]	new[221]	_	_
31-20	4674-4678	tail	object[221]	new[221]	_	_
31-21	4679-4681	of	object[221]	new[221]	_	_
31-22	4682-4685	the	object[221]|abstract[222]	new[221]|giv[222]	_	_
31-23	4686-4691	class	object[221]|abstract[222]	new[221]|giv[222]	_	_
31-24	4692-4693	D	object[221]|abstract[222]	new[221]|giv[222]	_	_
31-25	4694-4695	(	_	_	_	_
31-26	4696-4700	i.e.	object[223]	giv[223]	_	_
31-27	4701-4702	,	object[223]	giv[223]	_	_
31-28	4703-4706	the	object[223]	giv[223]	_	_
31-29	4707-4711	most	object[223]	giv[223]	_	_
31-30	4712-4719	similar	object[223]	giv[223]	_	_
31-31	4720-4729	scaffolds	object[223]	giv[223]	_	_
31-32	4730-4732	to	object[223]	giv[223]	_	_
31-33	4733-4734	A	object[223]|abstract	giv[223]|giv	_	_
31-34	4735-4736	,	object[223]	giv[223]	_	_
31-35	4737-4742	which	object[223]	giv[223]	_	_
31-36	4743-4746	are	object[223]	giv[223]	_	_
31-37	4747-4752	still	object[223]	giv[223]	_	_
31-38	4753-4760	largely	object[223]	giv[223]	_	_
31-39	4761-4769	inactive	object[223]	giv[223]	_	_
31-40	4770-4771	)	_	_	_	_
31-41	4772-4773	.	_	_	_	_
